Skip to main content
TipRanks
Go Ultimate75% OFF

Bio-Rad Laboratories, Inc. Class B (BIO.B) Q3 2026 Earnings Report

1 Followers

BIO.B Q3 2026 EPS Results

Actual EPS
$2.65
Consensus EPS
$2.23
Beat/Miss
Beat by +$0.42
One Year Ago EPS
$2.26

BIO.B Q3 2026 Revenue Results

Actual Revenue
$656.40M
Expected Revenue
$649.94M
Beat/Miss
Beat by +$6.46M
YoY Revenue Growth
+0.52%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
BIO.B Upcoming Earnings

Bio-Rad Laboratories, Inc. Class B's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

BIO.B Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-4.94%|
Earnings Call Sentiment|Positive

The call was cautiously positive. Management highlighted a return to currency-neutral revenue growth, improving non-GAAP margins, strong ddPCR instrument performance, renewed Diagnostics growth, product launches and progress on restructuring and productivity initiatives. These positives were offset by a full-year revenue outlook ranging from minus 3% to plus 0.5%, continued academic and government funding pressure, Life Science declines, China pricing and competitive challenges, logistics disruption, restructuring-related GAAP charges and a current operating margin that remains below the company's stated potential.

Company Guidance

Bio-Rad reaffirmed full year '26 currency-neutral revenue growth between minus 3% and plus 0.5%, with full year growth expected to be approximately at the midpoint of this range; Life Science currency-neutral revenue growth is expected between minus 3% and minus 1%, Clinical Diagnostics currency-neutral revenue growth between minus 3% and plus 1%, and Q3-to-Q4 reported revenue up 5% to 6%. Full year non-GAAP gross margin is expected in the upper half of the guidance range of between 53% and 54%, full year non-GAAP operating margin in the upper half of the guidance range of between 10% and 12%, and free cash flow in the range of approximately $290 million to $340 million; Q4 SG&A is expected to be flat to Q3, R&D is expected to step up $3 million sequentially, and depreciation and amortization is modeled at approximately $40 million. The Q4 outlook does not assume a recovery in academic and government end markets, and a sequential decline in Q4 gross margin is expected due to product mix shifting more toward instruments, the expected sequential decline in Process Chromatography revenue and higher fuel prices, which are expected to continue into '27. Management said it would be focused on driving towards positive growth rate in '27 and driving further margin expansion in '27, while the $30 million to $35 million restructuring savings remains intact, with full realization starting in '28; the $80 million to $90 million restructuring program is proceeding. The estimated China revenue impact from updated guidelines is in the middle single-digit millions of dollars in 2027, logistics disruption is contemplated to continue into 2027, and consumables pull-through could continue to not have normalized into 2027.

  • Expected Fourth-Quarter Revenue RampManagement expects reported revenue to increase 5% to 6% sequentially from the third quarter to the fourth quarter, in line with typical seasonality.
  • Board and Shareholder EngagementThe Board is evaluating candidates to add broader operational experience in life science tools and diagnostics. Management also said its dialogue with Elliott Management remains active and productive and that the parties are broadly aligned on objectives.
  • Balanced Capital Allocation FrameworkBio-Rad continues to invest in the business and innovation capabilities, intends to remain opportunistic rather than systematic with share repurchases, and is considering acquisitions with approximately $100 million to $500 million of revenue in the Diagnostics or life science tools areas. Management also reiterated that the Sartorius stake is a monetizable asset.
  • Return to Currency-Neutral Revenue GrowthThird-quarter revenue was approximately $656 million, up 0.5% on a reported basis and 0.7% on a currency-neutral basis versus the prior year. This was Bio-Rad's first quarter of currency-neutral growth in 2026.
  • Improved Non-GAAP ProfitabilityNon-GAAP gross margin expanded to 54.5% from 53.5% in the prior-year quarter and improved sequentially from 53.9%. Non-GAAP operating margin increased to 12.8% from 11.8% and from 12.5% in the second quarter of 2026.
  • Higher Non-GAAP Net Income and EPSThird-quarter non-GAAP net income increased to $72 million, or $2.65 diluted EPS, from $61 million, or $2.26 diluted EPS, in the prior-year quarter.
  • Clinical Diagnostics Returned to GrowthClinical Diagnostics revenue increased 2.7% on a reported basis and 2.8% on a currency-neutral basis to approximately $402 million. Growth was driven by timing of orders in Quality Systems and Diabetes products, with regional growth from the Americas and Asia Pacific.
  • Quality Controls and Diabetes StrengthQuality Controls, described as Bio-Rad's largest Diagnostics franchise and a market leader, continued to show strength globally. Diabetes also showed broad-based strength across regions throughout 2026.
  • Life Science Growth Excluding Process ChromatographyLife Science currency-neutral revenue excluding Process Chromatography increased 2.5% year-over-year, representing the third consecutive quarter of sequential improvement in the growth rate. The improvement was driven by the Genomics portfolio, including Droplet Digital PCR.
  • Strong Droplet Digital PCR Instrument PerformanceThe ddPCR portfolio delivered 7% currency-neutral growth, while instrument revenue increased more than 20% year-over-year for the third consecutive quarter. Performance was supported by conversions from traditional qPCR, competitive wins and the QX700 portfolio.
  • Improving Process Chromatography TrendProcess Chromatography revenue improved sequentially throughout 2026, and the company expects 2026 revenue to improve year-over-year despite anticipating a sequential decline in the fourth quarter.
  • Constructive Biopharma Demand TrendsBio-Rad reported signs of improving customer activity in biopharma. The recovery remains gradual, but management described the trends as constructive for demand over the coming years and said improvement has expanded from later-stage large pharma and biotech activity toward discovery.
  • Return to Growth in China During the QuarterChina returned to growth in the third quarter, largely driven by orders shifted from the second quarter and a favorable prior-year comparison. Quality Controls continued to be strong in the region.
  • AI and Productivity InitiativesBio-Rad is applying AI to internal processes to improve productivity, decision-making and execution, while also incorporating AI into products to improve their capabilities and customer value. Management said it expects AI-related customer activity to support more productive testing, reagent utilization and demand in academic research and drug discovery.
  • ChemiDoc Pro Launch AcceleratedBio-Rad launched the ChemiDoc Pro imaging system during the quarter. The launch was accelerated by approximately two quarters through product-development prioritization and execution improvements. Its analytical algorithm was developed using AI trained on thousands of western blot images.
  • Expansion of Chromatography PortfolioThe company expanded its Foresight Pro pre-packed chromatography column portfolio to include Nuvia resins, broadening the formats available to customers.
  • Operational Efficiency and Innovation FocusBio-Rad continues initiatives involving operational efficiency, procurement, inventory management and manufacturing-footprint optimization, alongside efforts to strengthen product development and establish a more consistent cadence of innovation.
  • Restructuring Savings Plan on TrackThe $80 million to $90 million restructuring program is proceeding. The company reiterated expected savings of $30 million to $35 million, with actions taking hold throughout the latter part of 2026 and throughout 2027, and full realization expected starting in 2028.
  • Cash Flow and Full-Year Margin Outlook ReaffirmedBio-Rad reaffirmed its 2026 free cash flow estimate of approximately $290 million to $340 million; it had generated $210 million through nine months. Full-year non-GAAP gross margin and operating margin are expected in the upper half of their respective guidance ranges of 53% to 54% and 10% to 12%.

BIO.B Earnings History

BIO.B earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 18, 20272026 (Q4)2.83-2.51――
Nov 04, 20262026 (Q3)2.232.652.2617.26% (+0.39)
Aug 04, 20262026 (Q2)1.782.622.610.38% (+0.01)
Apr 30, 20262026 (Q1)2.011.892.54-25.59% (-0.65)
Feb 12, 20262025 (Q4)2.692.512.9-13.45% (-0.39)
Oct 29, 20252025 (Q3)1.892.262.0112.44% (+0.25)
Jul 31, 20252025 (Q2)1.752.613.11-16.08% (-0.50)
May 01, 20252025 (Q1)1.822.542.2910.92% (+0.25)
Feb 13, 20252024 (Q4)2.862.903.1-6.45% (-0.20)
Oct 30, 20242024 (Q3)1.132.012.33-13.73% (-0.32)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed